<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our newly synthesized delta-(S-methylisothioureido)-L-norvaline (L-MIN) was shown to have potent inhibitory effects on Ca(2+)-dependent and constitutively expressed neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (type I NOS) when compared to other commonly recognized NOS inhibitors and produced an IC50 value of 5.7 nM </plain></SENT>
<SENT sid="1" pm="."><plain>By contrast, this compound exhibited more than 40-fold weaker inhibitory effects on the other NOS isoforms </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of L-MIN (0.1, 0.3 and 1 mg kg-1, i.p.) to rats immediately after 2 h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and 2 h reperfusion reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size in a dose-dependent manner </plain></SENT>
<SENT sid="3" pm="."><plain>These results suggest that type I NOS activation has a crucial role in the pathogenic cellular mechanisms underlying <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
</text></document>